nicotine replacement patches

Preclinical

nicotine replacement patches is one of 26 therapeutic programs targeting Smoking Cessation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Smoking CessationRecruiting

Smoking CessationPreclinical

Recruiting

Competition

Competitive Landscape

34 competitors in Smoking Cessation

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

70 2

Chantix

PPrism Pharmaceuticals

Approved

70 3

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

31 4

Viagra

VViatris Specialty LLC

Approved

1 5

Lunesta

Akero Therapeutics

Approved

1 6

Nicotine Free Cigarettes

Pfizer

Phase 3

28 7

Wellbutrin

GSK

Phase 3

5 8

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—9

Inderal

WWyeth-Lederle Vaccines

Nicotine Replacement

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Smoking Cessation

NCT07487818

Clinical

Trials by Indication[1]

Smoking Cessation1 trial

Using Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation

Recruiting·MMayo Clinic·Preclinical·NCT07487818·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for nicotine replacement patches. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for nicotine replacement patches. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMayo Clinic

nicotine replacement patches

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Smoking Cessation1 trial

References

Drug Info

Quick Facts

Related News